NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL — Stella

Recruiting

Back to Primary CNS Lymphoma (PCNSL) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(10 sites)

South Korea

Kosin University Gospel Hospital, Busan

Chonnam National University Hwasun Hospital, Hwasun

Korea National Cancer Center, Ilsan

Seoul National University Bundang Hospital, Seongnam

Asan Medical Center, Seoul

Key details

Phase

Safety & dosing

Sponsor

NOBO Medicine

Enrollment target

~33 participants

Started

November 2024

Primary completion

June 2026

Age range

19 Years – 80 Years

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov